Identification of c-MYC as a target of the APC pathway

被引:4035
|
作者
He, TC
Sparks, AB
Rago, C
Hermeking, H
Zawel, L
da Costa, LT
Morin, PJ
Vogelstein, B
Kinzler, KW
机构
[1] Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA
[2] Howard Hughes Med Inst, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21205 USA
[4] NIA, Baltimore, MD 21224 USA
关键词
D O I
10.1126/science.281.5382.1509
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The adenomatous polyposis coil gene (APC) is a tumor suppressor gene that is inactivated in most colorectal cancers. Mutations of APC cause aberrant accumulation of beta-catenin, which then binds T cell factor-4 (Tcf-4), causing increased transcriptional activation of unknown genes. Here, the c-MYC oncogene is identified as a target gene in this signaling pathway. Expression of c-MYC was shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c-MYC promoter. These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers.
引用
收藏
页码:1509 / 1512
页数:4
相关论文
共 50 条
  • [21] THE ORNITHINE DECARBOXYLASE GENE IS A TRANSCRIPTIONAL TARGET OF C-MYC
    BELLOFERNANDEZ, C
    PACKHAM, G
    CLEVELAND, JL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) : 7804 - 7808
  • [22] A correlation of APC and c-myc mRNA levels in lung cancer cell lines
    Jaiswal, AS
    Kennedy, CH
    Narayan, S
    ONCOLOGY REPORTS, 1999, 6 (06) : 1253 - 1256
  • [23] Regulation of RPE c-myc activity by the adenomatous polyposis coli (APC) gene
    Defoe, DM
    Marcus, DM
    Smith, SB
    Rustgi, AK
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 3488 - 3488
  • [24] Identification of c-myc as a down-stream target for pituitary tumor-transforming gene
    Pei, L
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (11) : 8484 - 8491
  • [25] In silico identification of transcriptional regulators associated with c-Myc
    Elkon, R
    Zeller, KI
    Linhart, C
    Dang, CV
    Shamir, R
    Shiloh, Y
    NUCLEIC ACIDS RESEARCH, 2004, 32 (17) : 4955 - 4961
  • [26] APC pathway including beta-catenin, c-MYC, and pS2 protein in intestinal type of stomach cancer
    Chang, HK
    3RD INTERNATIONAL GASTRIC CANCER CONGRESS, 1999, : 339 - 342
  • [27] DKC1 is an evolutionarily conserved c-Myc target
    Alawi, Faizan
    Lee, Megan
    FASEB JOURNAL, 2007, 21 (06): : A1155 - A1155
  • [28] The role of the c-myc oncogene as a target for gene therapy in melanoma
    Tulley, P
    Chana, JS
    Grover, R
    Wilson, GD
    Sanders, R
    HUMAN GENE THERAPY, 1999, 10 (05) : 851 - 851
  • [29] C-MYC ONCOGENE EXPRESSION IS NOT THE TARGET FOR VERAPAMILS ANTIPROLIFERATIVE EFFECT
    HUBER, KR
    SCHMIDT, WF
    NEUBERG, RW
    ETTINGER, RS
    CLINICAL RESEARCH, 1988, 36 (01): : A69 - A69
  • [30] BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
    Delmore, Jake E.
    Issa, Ghayas C.
    Lemieux, Madeleine E.
    Rahl, Peter B.
    Shi, Junwei
    Jacobs, Hannah M.
    Kastritis, Efstathios
    Gilpatrick, Timothy
    Paranal, Ronald M.
    Qi, Jun
    Chesi, Marta
    Schinzel, Anna C.
    McKeown, Michael R.
    Heffernan, Timothy P.
    Vakoc, Christopher R.
    Bergsagel, P. Leif
    Ghobrial, Irene M.
    Richardson, Paul G.
    Young, Richard A.
    Hahn, William C.
    Anderson, Kenneth C.
    Kung, Andrew L.
    Bradner, James E.
    Mitsiades, Constantine S.
    CELL, 2011, 146 (06) : 903 - 916